Related Experiment Videos
The future of recombinant growth factors in wound healing
M C Robson1, T A Mustoe, T K Hunt
1Institute for Tissue Regeneration, Repair and Rehabilitation, Bay Pines, Florida 33744, USA.
Abstract:
For more than a decade, clinical trials have been conducted of the application of topical exogenous recombinant growth factors in attempts to accelerate the healing of chronic wounds. Although the results of some of these trials have been encouraging, overall the results have been somewhat discouraging. Much of the difficulty lies in the paucity of carefully controlled clinical trials of wound healing. Since wound healing is a complex process that can be influenced, both positively and negatively, by many factors, designing these trials has proved difficult. To date, only a single recombinant growth factor-recombinant human platelet-derived growth factor-BB (rhPDGF-BB)- has been approved by the US Food and Drug Administration; and that only for use in diabetic foot ulcers. It is unlikely, however, that a single growth factor will be able to resolve all issues of repair or strengthen all vulnerabilities of chronic wounds. Our expectation, therefore, is that growth factors, cytokines, and other biologic agents will be used more specifically in the future, for example, by targeting growth factor therapy at those specific components or processes that a given wound uses to heal.
Insights
Clinical trials using topical recombinant growth factors for chronic wound healing show mixed results. Future therapies may target specific wound healing processes with tailored biologic agents.
Area of Science:
- Regenerative Medicine
- Wound Healing Research
- Biologics in Therapeutics
Background:
- Topical exogenous recombinant growth factors have been investigated for over a decade to accelerate chronic wound healing.
- Clinical trial outcomes have been inconsistent, with some encouraging results but overall discouraging trends.
- The complexity of wound healing and challenges in designing controlled trials contribute to the difficulties.
Purpose of the Study:
- To review the progress and challenges in applying recombinant growth factors for chronic wound healing.
- To discuss the limitations of current approaches and the potential for future therapeutic strategies.
Main Methods:
- Analysis of clinical trial data on topical recombinant growth factors for chronic wound healing.
- Discussion of the complexities involved in designing and conducting wound healing clinical trials.
- Review of the current regulatory status of growth factors in wound care.
Main Results:
- Only one recombinant growth factor, recombinant human platelet-derived growth factor-BB (rhPDGF-BB), is FDA-approved, exclusively for diabetic foot ulcers.
- The efficacy of single growth factors in addressing all chronic wound complexities remains limited.
- Significant challenges persist in the design and execution of rigorously controlled clinical trials.
Conclusions:
- A single growth factor is unlikely to be a universal solution for all chronic wound repair issues.
- Future therapeutic approaches are expected to involve more specific applications of growth factors, cytokines, and other biologic agents.
- Targeted therapies focusing on specific wound healing components or processes hold promise for improved outcomes.